celecoxib Articles
Celebrex wins new indication, for FAP
15 December 1999
Monsanto to spin off pharma operations?
13 December 1999
Stock Commentary New York
9 December 1999
Stock Commentary Tokyo
9 December 1999
Pharmaceutical industry must adapt to age of individualized health
26 November 1999
Merck & Co goes once-weekly with osteoporosis drug Fosamax
24 November 1999
Yamanouchi watching Lipitor developments
24 November 1999
Stock Commentary Tokyo
18 November 1999
Daiichi Pharma sales growth slower; Harmokisan approval delayed
15 November 1999
Novartis link-up with Monsanto mooted
10 November 1999
COX-2 inhibition in cancer prevention?
29 October 1999
Merck's osteoarthritis drug in menstrual pain
21 October 1999
Merck victorious in COX-2 patent dispute
11 October 1999
Novartis Trileptal approvable in USA; firm building broad franchise in
30 September 1999
COX-2 inhibitors boost US drug sales
22 September 1999
COX-2 inhibitors: potential in colon cancer?
9 September 1999
Celebrex to be fast-tracked for new indication
2 September 1999
Pfizer/Monsanto act on drug name confusion
1 September 1999
Celebrex sales drive Monsanto earnings rise
29 July 1999
Vioxx hot on the tails of Celecoxib
15 July 1999
Early US Rx data for Merck & Co's Vioxx
9 June 1999
Stock Commentary Tokyo
6 May 1999
Stock Commentary Tokyo
29 April 1999
Celebrex launched in Canada
29 April 1999
First Euro approval for Searle's Celebrex
13 April 1999
First launch of Merck's Vioxx in Mexico
29 March 1999
Stock Commentary Tokyo
29 March 1999
Vioxx could debut in Mexico this month
17 March 1999
Mail-order Rxs boost Searle/Pfizer Celebrex
16 March 1999
Mobic's US prospects boosted by Abbott deal
11 March 1999
Merck & Co's Vioxx to get FDA review in April
4 March 1999
Future growth of the global pharmaceutical market evaluated by MSDW
23 February 1999
FDA recommends approval of Pfizer's Tikosyn
3 February 1999
Second approval for celecoxib in Brazil
27 January 1999
Merck disappointment as highly-touted antidepressant stalls
26 January 1999
Stock Commentary New York
20 January 1999
Vioxx to mount strong challenge to Celebrex
14 January 1999
Stock Commentary New York
7 January 1999
Celebrex Recommended For US Approval
2 December 1998
Analysts Taking Stock Of Pharma Firms, Prospects Still Good
26 November 1998
US Insurers Ponder COX-2 Inhibitors
23 November 1998
Pivotal Studies Of Celebrex Unveiled At ACR
19 November 1998
Phase III Rofecoxib Data In Osteoarthritis
12 November 1998
Pfizer Aims For Top Slot After Millenium
10 November 1998
Goldman Sachs, MSDW Top II's 1998 Analysts List
10 November 1998
Healthy Third-Quarter Growth For US Drug Majors
22 October 1998
After AHP/Monsanto Collapse, M&As Unlikely?
16 October 1998
US Majors Post Strong Earnings For 3rd Quarter
15 October 1998
Stock Commentary
24 September 1998
Stock Commentary New York
17 September 1998
Priority FDA Review For Searle's Celebra
25 August 1998
Pfizer Claims "Unsurpassed Prospects"
29 July 1998
Astra To End Partnership In USA With Merck?
15 June 1998
Astra To End Partnership In USA With Merck?
10 June 1998
Collaborations And Licensing News In Brief
26 March 1998
Biotech Promise For Rheumatoid Arthritis
26 February 1998
Pfizer Licenses Searle's Celecoxib For Arthritis
24 February 1998
Celecoxib In Cancer
19 February 1998
Monsanto Stock Rises Before Searle Meeting
2 February 1998
Yamanouchi Signs Alliance With Searle
20 January 1998
First Ph III Data With Searle's Celecoxib
20 November 1997
Solid Growth For US Firms Despite Strong $
24 July 1997
Celecoxib Promise In Arthritis
19 June 1997
Searle Reports Progress With COX-2 Inhibitor
21 October 1996
Yamanouchi To Develop Searle's Celecoxib In Japan
29 April 1996
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
